Globeflex Capital L P Grows Stock Position in Atara Biotherapeutics, Inc. $ATRA

Globeflex Capital L P boosted its holdings in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) by 399.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 77,224 shares of the biotechnology company’s stock after acquiring an additional 61,766 shares during the quarter. Globeflex Capital L P owned about 1.07% of Atara Biotherapeutics worth $1,397,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of ATRA. Marshall Wace LLP acquired a new stake in shares of Atara Biotherapeutics during the second quarter valued at $327,000. Mackenzie Financial Corp boosted its stake in shares of Atara Biotherapeutics by 183.5% during the third quarter. Mackenzie Financial Corp now owns 63,816 shares of the biotechnology company’s stock valued at $914,000 after acquiring an additional 41,302 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Atara Biotherapeutics by 6.6% during the third quarter. Vanguard Group Inc. now owns 203,438 shares of the biotechnology company’s stock valued at $2,915,000 after acquiring an additional 12,677 shares during the last quarter. GSA Capital Partners LLP boosted its stake in shares of Atara Biotherapeutics by 33.8% during the third quarter. GSA Capital Partners LLP now owns 26,213 shares of the biotechnology company’s stock valued at $376,000 after acquiring an additional 6,622 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of Atara Biotherapeutics during the second quarter valued at $31,000. Hedge funds and other institutional investors own 70.90% of the company’s stock.

Atara Biotherapeutics Trading Up 7.1%

Shares of NASDAQ:ATRA opened at $10.31 on Friday. The stock’s 50-day moving average price is $6.96 and its two-hundred day moving average price is $8.77. Atara Biotherapeutics, Inc. has a 12-month low of $3.92 and a 12-month high of $19.15. The firm has a market cap of $92.89 million, a price-to-earnings ratio of -15.39 and a beta of 0.11.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04. Atara Biotherapeutics had a negative return on equity of 79.12% and a negative net margin of 40.91%.The firm had revenue of $0.52 million for the quarter, compared to analyst estimates of $2.90 million. As a group, research analysts forecast that Atara Biotherapeutics, Inc. will post 0.2 earnings per share for the current fiscal year.

Insider Transactions at Atara Biotherapeutics

In other Atara Biotherapeutics news, CEO Anhco Nguyen sold 5,241 shares of the firm’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $9.13, for a total value of $47,850.33. Following the sale, the chief executive officer directly owned 137,837 shares of the company’s stock, valued at approximately $1,258,451.81. This trade represents a 3.66% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, major shareholder Innovation Ltd Panacea sold 313,446 shares of the firm’s stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $10.10, for a total value of $3,165,804.60. Following the completion of the sale, the insider directly owned 1,011,000 shares in the company, valued at approximately $10,211,100. The trade was a 23.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 321,101 shares of company stock worth $3,235,695. 41.20% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

ATRA has been the topic of a number of analyst reports. Freedom Capital raised Atara Biotherapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, May 18th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Atara Biotherapeutics in a research note on Friday, March 27th. Canaccord Genuity Group set a $13.00 price objective on Atara Biotherapeutics and gave the company a “buy” rating in a research note on Friday, May 8th. Finally, Wall Street Zen raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Atara Biotherapeutics has an average rating of “Hold” and a consensus price target of $9.50.

Atara Biotherapeutics Profile

Atara Biotherapeutics, Inc is a biotechnology company focused on the discovery, development and commercialization of novel T-cell immunotherapies to transform the treatment of cancer and autoimmune disease. Headquartered in South San Francisco, California, Atara leverages its proprietary off-the-shelf allogeneic Epstein-Barr virus (EBV)-directed T-cell platform to generate engineered cell therapies designed to target EBV-driven malignancies and immune-mediated disorders.

The company’s lead product candidate, tabelecleucel, is an off-the-shelf, EBV-specific T-cell therapy in clinical development for the treatment of EBV-positive post-transplant lymphoproliferative disease (PTLD) and other EBV-associated cancers.